Literature DB >> 3312244

Growth regulation of human breast carcinoma occurs through regulated growth factor secretion.

M E Lippman1, R B Dickson, E P Gelmann, N Rosen, C Knabbe, S Bates, D Bronzert, K Huff, A Kasid.   

Abstract

We describe studies on human breast cancer in which it is shown that specific growth factors (IGF-I, TGF alpha, PDGF) are secreted by human breast cancer cells and likely to be involved in tumor growth and progression. These activities are regulated by estradiol in hormone-dependent breast cancer and secreted constitutively by hormone-independent cells. These growth factor activities can induce the growth of hormone-dependent cells in vivo in athymic nude mice. Hormone-dependent breast cancer cells also secrete TGF beta, a growth-inhibitory substance, when treated with antiestrogens. TGF beta functions as a negative autocrine growth regulator and is responsible for some of the growth-inhibitory effects of antiestrogens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312244     DOI: 10.1002/jcb.240350102

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  26 in total

1.  IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study.

Authors:  C Giani; K J Cullen; D Campani; A Rasmussen
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation.

Authors:  M Kaleko; W J Rutter; A D Miller
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

Review 3.  Molecules, cancer, and the surgeon. A review of molecular biology and its implications for surgical oncology.

Authors:  J M Arbeit
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

4.  Stromal IGF-II messenger RNA in breast cancer: relationship with progesterone receptor expressed by malignant epithelial cells.

Authors:  C Giani; A Pinchera; A Rasmussen; P Fierabracci; R Bonacci; D Campini; G Bevilacqua; B Trock; M E Lippman; K J Cullen
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

5.  Growth-promoting effects of gastrin on mouse colon cancer cells in vitro: absence of autocrine effects.

Authors:  Y S Guo; M Baijal; G F Jin; J C Thompson; C M Townsend; P Singh
Journal:  In Vitro Cell Dev Biol       Date:  1990-09

6.  Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014.

Authors:  J M Kuhn; C Basin; M Mollard; B de Rougé; C Baudoin; R Obach; G Tolis
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  PDGF-A promoter and enhancer elements provide efficient and selective antineoplastic gene therapy in multiple cancer types.

Authors:  A Mishra; A K Ormerod; M L Cibull; B T Spear; S D Kraner; D M Kaetzel
Journal:  Cancer Gene Ther       Date:  2008-11-07       Impact factor: 5.987

8.  Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.

Authors:  K Szepeshazi; S Milovanovic; K Lapis; K Groot; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

9.  Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer.

Authors:  L Seymour; D Dajee; W R Bezwoda
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.

Authors:  S R Milovanovic; E Monje; K Szepeshazi; S Radulovic; A Schally
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.